» Articles » PMID: 36011411

MiR-18a-5p Targets Connective Tissue Growth Factor Expression and Inhibits Transforming Growth Factor β2-Induced Trabecular Meshwork Cell Contractility

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2022 Aug 26
PMID 36011411
Authors
Affiliations
Soon will be listed here.
Abstract

Increased trabecular meshwork (TM) cell and tissue contractility is a driver of the reduced outflow facility and elevation of intraocular pressure (IOP) associated with primary open-angle glaucoma (POAG). Connective tissue growth factor (CTGF) is an established mediator of TM cell contractility, and its expression is increased in POAG due to transforming growth factor β 2 (TGFβ2) signalling. Inhibiting CTGF upregulation using microRNA (miRNA) mimetics could represent a new treatment option for POAG. A combination of in silico predictive tools and a literature review identified a panel of putative CTGF-targeting miRNAs. Treatment of primary human TM cells with 5 ng/mL TGFβ2 for 24 h identified miR-18a-5p as a consistent responder, being upregulated in cells from five different human donors. Transfection of primary donor TM cells with 20 nM synthetic miR-18a-5p mimic reduced TGFβ2-induced CTGF protein expression, and stable lentiviral-mediated overexpression of this miRNA reduced TGFβ2-induced contraction of collagen gels. Together, these findings identify miR-18a-5p as a mediator of the TGFβ2 response and a candidate therapeutic agent for glaucoma via its ability to inhibit CTGF-associated increased TM contractility.

Citing Articles

Investigating the miRNA-mRNA interactome of human trabecular meshwork cells treated with TGF-β1 provides insights into the pathogenesis of pseudoexfoliation glaucoma.

Roodnat A, Doyle C, Callaghan B, Lester K, Henry M, Sheridan C PLoS One. 2025; 20(1):e0318125.

PMID: 39883689 PMC: 11781692. DOI: 10.1371/journal.pone.0318125.


Evaluating the efficacy and safety of polyglycolic acid-loading mitomycin nanoparticles in inhibiting the scar proliferation after glaucoma filtering surgery.

Li T, Tang J, Li C, Liu G, Li Y, Guo S Ann Med. 2024; 57(1):2436458.

PMID: 39632730 PMC: 11622377. DOI: 10.1080/07853890.2024.2436458.


The TGFβ Induced MicroRNAome of the Trabecular Meshwork.

Doyle C, Callaghan B, Roodnat A, Armstrong L, Lester K, Simpson D Cells. 2024; 13(12.

PMID: 38920689 PMC: 11201560. DOI: 10.3390/cells13121060.


Glaucoma: Novel antifibrotic therapeutics for the trabecular meshwork.

Qin M, Yu-Wai-Man C Eur J Pharmacol. 2023; 954:175882.

PMID: 37391006 PMC: 10804937. DOI: 10.1016/j.ejphar.2023.175882.


The Importance of MicroRNA Expression in Pseudoexfoliation Syndrome.

Tomczyk-Socha M, Tomczak W, Turno-Krecicka A Int J Mol Sci. 2022; 23(21).

PMID: 36362020 PMC: 9653611. DOI: 10.3390/ijms232113234.

References
1.
Drewry M, Helwa I, Allingham R, Hauser M, Liu Y . miRNA Profile in Three Different Normal Human Ocular Tissues by miRNA-Seq. Invest Ophthalmol Vis Sci. 2016; 57(8):3731-9. PMC: 4961003. DOI: 10.1167/iovs.16-19155. View

2.
Chou C, Shrestha S, Yang C, Chang N, Lin Y, Liao K . miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2017; 46(D1):D296-D302. PMC: 5753222. DOI: 10.1093/nar/gkx1067. View

3.
Keller K, Aga M, Bradley J, Kelley M, Acott T . Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2008; 88(4):676-82. PMC: 2700052. DOI: 10.1016/j.exer.2008.11.023. View

4.
Wormald R, Virgili G, Azuara-Blanco A . Systematic reviews and randomised controlled trials on open angle glaucoma. Eye (Lond). 2019; 34(1):161-167. PMC: 7002425. DOI: 10.1038/s41433-019-0687-5. View

5.
Huntzinger E, Izaurralde E . Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011; 12(2):99-110. DOI: 10.1038/nrg2936. View